The PennZone

  • Home
  • Entertainment
  • Marketing
  • Music
  • Non-profit
  • Books
  • Artificial Intelligence
  • Education
  • Automotive

Rimsys’ 2023 Regulatory Performance Report Finds a Growing Emphasis on Digital Transformation in MedTech Regulatory Affairs
The PennZone/10219057

Trending...
  • Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
  • Slotozilla Reports Strong Growth in Q2 2026
  • Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety
PITTSBURGH--(BUSINESS WIRE)--Rimsys, the leading provider of Regulatory Information Management (RIM) software for the medtech industry, today announced the release of the 2023 Regulatory Performance Report, a new study that tracks trends in regulatory priorities, processes, and performance within medtech companies. The report is based on a survey of 200 regulatory professionals and executives across North America and Europe.

The report explores how regulatory affairs teams are staffed, their workload, average times to complete regulatory projects, where they experience compliance issues, and the growing trend of accelerating digital transformation within the industry.

"The need for this report was driven by conversations with several of our customers," said James Gianoutsos, Founder and CEO of Rimsys. "Regulatory leaders don't have clear benchmarks to measure the performance of their teams. They're looking at digital transformation initiatives to improve the efficiency and effectiveness of their teams and want to understand what's possible, what really good execution looks like."

Key findings include:

Regulatory teams are lightly staffed compared to their workload.

A quarter of large medtech companies have 15 or fewer regulatory employees. These small teams complete over 100 renewals or license updates each year. Only 13% of companies make resourcing decisions based on anticipated workload, leaving any gaps to be filled with external consultants. Today, 90% of companies rely on consultants to complete regulatory projects.

Process failures are common.

Regulatory leaders self-assess the performance of their teams highly. A majority believe they outperform other regulatory affairs teams in similar companies in both project planning and execution. Yet over 60% reported a major non-compliance issue in that past year, and 24% had to withdraw products from a country or region due to non-compliance.

More on The PennZone
  • Grace Montessori School Earns Prestigious American Montessori Society Accreditation
  • Revenue Optics Launches Pricing and Revenue Growth Management Practice, Names Shafohi Alamgir Vice President
  • Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support
  • CasaPerks and CredHub Partner to Help the Multifamily Industry Strengthen Resident Activation Through Credit-Building Rewards
  • NaturismRE expands international research programme with Health & Wellbeing Survey

Digital transformation makes a measurable impact on productivity.

Companies are investing in process improvement, both by increasing staffing and growing technology budgets. They are moving away from generic productivity tools to more specialized solutions designed for regulatory processes. Companies that have implemented regulatory information management and regulatory intelligence systems report very high productivity gains and they complete regulatory projects more quickly.

Rimsys and PA Consulting, a global innovation and transformation consultancy, in conjunction with the Regulatory Affairs Professionals Society, will be presenting and discussing the survey findings in an interactive webinar on February 23, 2023. To attend, register here: https://bit.ly/performance-study-webinar.

"A major trend we are tracking this year is focused on Medtech's engagement with regulatory bodies against a backdrop of new requirements for advanced technologies such as AI, and evolving legislation such as the MDR and IVDR transition in Europe. This has forced organizations to re-evaluate old processes and adopt new tools," said Marck Aghnatios, MedTech Expert at PA Consulting. "The impact of this change will be largely absorbed by the regulatory affairs function – which is accurately reflected Rimsys' study findings. The industry imperative for medtech leaders will be to digitize their business functions – starting with regulatory."

Methodology

More on The PennZone
  • L2 Aviation and Gotonomi Extend UAV Connectivity Beyond Cellular Reach
  • LATO AI Solidifies Future in Pittsburgh with North Shore Headquarters
  • Re:InvestorHub Launches the First AI-Powered Operating System Built for Real Estate Investors
  • Nadi Plumbing Leads Charlotte in Private Fire Hydrant Services, Eyes Regional Expansion
  • Obsolete Industrial Expands Its Membership

Rimsys worked with a third-party market research firm to field and administer the survey in July 2022. Survey respondents included 200 regulatory professionals at medtech (medical device, in vitro diagnostic, and software as a medical device) companies headquartered in the United States, Canada, and the European Union. Companies were evenly sampled across all sizes, from $10 million to more than $1 billion in revenue.

To download the full Regulatory Performance report, please visit: https://www.rimsys.io/regulatory-performance-report.

About Rimsys

Rimsys is improving global health by accelerating delivery and increasing availability of life-changing medical technologies. Rimsys Regulatory Information Management (RIM) software digitizes and automates regulatory activities, helping medtech regulatory affairs teams to plan more effectively, execute more quickly, and confidently ensure global regulatory compliance. Unlike complex, color-coded spreadsheets, or expensive external consultants, Rimsys centralizes all regulatory information, automates submission processes, and provides detailed visibility into product registrations, expirations, relevant standards, and global regulations. Traditional approaches to regulatory affairs can't keep pace with the growing complexity of the global landscape, and overburdened teams face increasing compliance risks. Rimsys is designed around medtech regulations and workflows and supports a full breadth of regulatory activities including registrations, submissions, UDI, essential principles, standards management, and regulatory intelligence in a single, integrated platform. Leading global medtech companies including Johnson & Johnson, Siemens Healthineers, and Omron rely on Rimsys to better manage regulatory projects and resources, get new products to market more quickly, and reduce revenue risk of non-compliance, product recalls, and unexpected expirations. For more information, visit www.rimsys.io.​

Contacts

Michael Peach
(855) 846-7269
michael.peach@rimsys.io
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Independent Colbert Packaging Thrives Amid Industrywide Consolidation
  • Free Commercial Glass Estimating and Code Compliance Tools Launched by Landmark Construction - The Leading Glass Company in Los Angeles
  • Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
  • Slotozilla Reports Strong Growth in Q2 2026
  • Eric Snyder, President and Chief Executive Officer of Keystone Consulting Engineers Named to LVB 300
  • Philadelphia's Girls Anthem to Host The Locker Room Experience Pop-Up for Young Women
  • Flexible Plan Investments Names Carl Resnick President
  • Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety
  • Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
  • No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
  • The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
  • Sharon Pinkenson Chosen as Philly Girl Top 40 Winner
  • Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
  • Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
  • San Diego Attorney Anthony Z. Vargas Narrows Practice to Employment Law, Representing Employees Only
  • Solid Earth Introduces RealtyID, a Universal Identity Spine for the Real Estate Industry
  • GGILabs Expands Local SEO Services to Help Businesses Compete in AI-Driven Search
  • Sara Viteri, Turnstone Creative Senior Producer, Named to Lehigh Valley Business' Forty Under 40

Popular on PennZone

  • Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community - 720
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments - 109
  • Leeds Billboard Campaign Drives 188% Traffic Uplift as AI Enquiries Rise 266% for Loud! OOH - 104
  • Sister Files Lawsuit Against Georgia Funeral Home for Alleged Mishandling of Brother's Remains
  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Board of Directors
  • $40 Billion Global Market Value by 2030 Projected in Unmanned Aerial Vehicle or Other Drone Technology Sector, Growing at 9.2% Compound Annual Growth
  • AI, Drones, Defense & Explosive Growth: Why ZenaTech Is Emerging as One of the Most Compelling Technology Growth Stories (N A S D A Q: ZENA)
  • Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
  • Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism

Similar on PennZone

  • When the Coroner's Report Isn't Enough: Colorado Families Turn to Private Autopsy for Closure
  • New Analysis Details Three Converging Forces in AI and Workforce Policy Behind a $37 Billion GDP Reduction
  • Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support
  • Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event
  • Real Estate Syndication Attorney Tilden Moschetti Releases The Real Estate Private Equity Blueprint
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
  • Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
  • Slotozilla Reports Strong Growth in Q2 2026
  • Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us